Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023

Accesswire November 14, 2023

Moderna to Present at Upcoming Conferences in November 2023

Accesswire November 8, 2023

Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event

Accesswire November 8, 2023

Moderna Tops BioSpace's Best Places to Work Ranking for Third Consecutive Year

Accesswire November 7, 2023

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates

Accesswire November 2, 2023

Flagship Pioneering Launches Pioneering Intelligence

PR Newswire November 1, 2023

CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission

Accesswire October 30, 2023

Moderna Named a Top Employer by Science for Ninth Consecutive Year

Accesswire October 26, 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19

Accesswire October 24, 2023

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

PR Newswire October 24, 2023

Moderna to Host Second Digital Investor Event on November 8th, 2023

Accesswire October 19, 2023

Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Accesswire October 12, 2023

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19

Accesswire October 4, 2023

Moderna Recommends Shareholders Reject Amended "Mini-Tender" Offer by TRC Capital Investment Corporation

Accesswire September 29, 2023

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in The European Union

Accesswire September 14, 2023

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Accesswire September 13, 2023

Health Canada OKs Moderna’s new COVID shot for kids 6 months and up

Jonathon Brown September 12, 2023

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine

Accesswire September 11, 2023

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

PR Newswire September 11, 2023

Moderna Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation

Accesswire September 8, 2023